. Correlation of ASPM (A) and E2F1 (B) expression and overall survival in gastric cancer by use of the Kaplan-Meier Plotter online tool with exclusion of dataset GSE62554 (ASPM probes, 219918_s_at, 232238_at and 239002_at; E2F1 probes, 2028_s_at and 204947_at). HR, hazard ratio.
cancers expressing high levels of ASPM had a better prognosis than those with low levels of ASPM, whereas high expression of E2F1 indicated a poor prognosis.
We appreciate that Wang et al found higher expression of ASPM in gastric cancer biopsies than in normal mucosa, strengthening our previous results [1] . Furthermore, Wang et al claim that stem cell markers should be more highly expressed in poorly differentiated tumours, and, because ASPM seemingly is not, they argue against ASPM's possible role as a novel stem cell marker. However, the difference in expression between the two tumour histological grades in their figure is at best very modest, and, because they have not described statistical methods and p-value corrections for their analysis, it is difficult to evaluate it properly. Also, the role of stem cells in gastric carcinogenesis is not fully understood, and the expression of established stem cell markers in gastric cancers varies.
Author reply to Letter to the Editor 563
In human gastric cancer biopsies, both LGR5 mRNA and the number of LGR5-positive cells are increased as compared with non-neoplastic mucosa [4] . Interestingly, the presence of LGR5-positive cells at the luminal surface was associated with increased patient survival, whereas LGR5 expression in the tumour centre and at the invasion front correlated with local tumour growth, nodal spread, tumour stage, and shorter overall survival [4] . Expression of BMI1 (protein) and LGR5 (mRNA and protein) is negatively correlated with the differentiation status of gastric cancer biopsies, with few BMI1-expressing and LGR5-expressing cells being present in poorly differentiated tumours [5] . When the expression of LGR5 in gastric cancer specimens was analysed with in situ hybridization, expression of LGR5 seemed to decline with dedifferentiation and progression into poorly differentiated adenocarcinomas [6, 7] . In the human stomach mucosa, the novel stem cell marker Troy [8] is expressed in normal pit, parietal and chief cells, and, in gastric cancer biopsies, expression of Troy is negatively correlated with tumour grade, nodal spread, and patient survival (intestinal-type gastric cancer) [9] .
In contrast, expression of the cancer stem cell marker CD44 [10] is more frequent in poorly differentiated/undifferentiated than in well/moderately differentiated gastric adenocarcinomas, and is associated with worse overall survival, whereas expression of the putative stem cell markers Musashi-1 and CD133 does not correlate with differentiation status [11] . In summary, the expression patterns of putative stem cell markers in gastric adenocarcinomas are heterogeneous, and thus it is plausible that a novel stem cell marker could be expressed at a lower level in poorly than in moderately differentiated tumours. Also, we suggest ASPM as a possible novel stem or progenitor cell marker. The two entities have very different capacities and potentials, and will probably diverge in their expression during the course of carcinogenesis.
When we re-analysed the association between expression of ASPM in gastric cancer and overall survival by use of the Kaplan-Meier Plotter with exclusion of dataset GSE62254, owing to markedly different characteristics, as recommended by the tool website when all samples are used together (http://kmplot.com/analysis/), we generated results opposite to those of Wang et al. In our analysis, high expression of ASPM was associated with worse overall survival than low expression for two out of three probes (Figure 1 ), whereas the third probe showed no significant difference. In this adjusted analysis, the ASPM expression level was also related to survival similarly to its putative transcription factor E2F1.
Altogether, in our opinion, the evidence and literature references presented here abate the controversy regarding the role of ASPM in gastric carcinogenesis as presented in the letter of Wang et al, and show that ASPM still might represent a novel stem cell marker that is possibly involved in gastric carcinogenesis. As we write in our article [1] , we fully agree that more studies are needed, but we are hesitant about how much analyses such as that presented by Wang et al contribute to elucidating further the possible roles of ASPM and E2F1 in this complex matter.
